Cargando…
Plasmid DNA vaccine coding eight repeats of gonadotrophin-releasing hormone induced atrophy of prostate in male mice
BACKGROUND: Prostate hyperplasia and neoplasia are major illness of men and elderly dogs. Treatment of prostate cancer requires androgen deprivation surgery or therapy to prevent metastases and alleviate pain. Recently, six DNA vaccines have entered clinical trials against prostate cancer in humans...
Autores principales: | Rima, Umme K., Bari, Abu S.M., Hossain, Mohammad Z., Khan, Mohammad A.H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Pacific Prostate Society
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251954/ https://www.ncbi.nlm.nih.gov/pubmed/30505818 http://dx.doi.org/10.1016/j.prnil.2018.01.001 |
Ejemplares similares
-
Gonadotrophin releasing hormone antagonist in IVF/ICSI
por: MS, Kamath, et al.
Publicado: (2008) -
Comparison of clinical outcomes between the depot gonadotrophin-releasing hormone agonist protocol and gonadotrophin-releasing hormone antagonist protocol in normal ovarian responders
por: Xia, Min, et al.
Publicado: (2021) -
Myopic Progression in Girls with Gonadotrophin-Releasing Hormone Agonist Treatment for Central Precocious Puberty
por: Chung, Seung Ah, et al.
Publicado: (2021) -
The effect of gonadotrophin-releasing hormone agonist versus human chorionic gonadotrophin trigger on pregnancy and neonatal outcomes in Letrozole-HMG IUI cycles
por: Chen, Li, et al.
Publicado: (2023) -
Using automated imaging to interrogate gonadotrophin-releasing hormone receptor trafficking and function
por: Armstrong, S.P., et al.
Publicado: (2011)